| Bioactivity | Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3]. |
| Target | CD4. |
| Invitro | Tregalizumab 能够激活调节性 T 细胞的抑制能力[1]。Tregalizumab 减少用破伤风类毒素刺激 (以剂量依赖性方式) 分离的 PBMC 的增殖和细胞因子分泌[1]。Tregalizumab (0-30 µg/mL; 18 h) 处理 PBMC 诱导 T 细胞的 CD4 下调[2]。Tregalizumab 主要诱导炎症部位的 CD4 下调[2]。 Cell Viability Assay[2] Cell Line: |
| Name | Tregalizumab |
| CAS | 1207446-68-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. König M, et al. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol. 2016 Jan 25;7:11. [2]. Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep. 2015 Dec 16;5:18308. [3]. Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405. |